---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-010598"
form_type: "8-K"
ticker: "NXTC"
cik: "0001661059"
company_name: "NextCure, Inc."
filed_at: "2024-08-01T23:59:59+00:00"
generated_at: "2026-05-31T13:51:29.757212+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# NextCure reports Q2 net loss $15.4M; cash $86.4M; LNCB74 IND on track for year-end

## Summary
- Net loss $15.4M in Q2 2024 vs $17.9M in Q2 2023; R&D expenses $12.4M (down from $13.4M).
- Cash & marketable securities $86.4M as of June 30, 2024; expected to fund operations into H2 2026.
- LNCB74 (B7-H4 ADC) GLP tox studies completed; IND submission planned by year-end 2024.
- NC410 + pembrolizumab ovarian cohort enrollment completed (16 additional patients); data expected Q4 2024.
- NC181 (Alzheimer's) manufacturing initiated for tox studies; seeking partnering/funding for IND mid-2025.

## SEC filing metadata
- accession: 0001558370-24-010598
- form_type: 8-K
- ticker: NXTC
- cik: 0001661059
- company_name: NextCure, Inc.
- filed_at: 2024-08-01T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1661059/000155837024010598/0001558370-24-010598-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1661059/000155837024010598/nxtc-20240801x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-010598
- JSON: https://secwatch.observer/filing/0001558370-24-010598.json
- Plain text: https://secwatch.observer/filing/0001558370-24-010598.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.